solifenacin succinate has been researched along with Urinary Bladder, Overactive in 298 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 59 (19.80) | 29.6817 |
| 2010's | 193 (64.77) | 24.3611 |
| 2020's | 46 (15.44) | 2.80 |
| Authors | Studies |
|---|---|
| Habeš, Dominik; Kestřánek, Jan; Leško, Daniel; Špaček, Jiří; Štěpán, Martin | 1 |
| Aydh, A; Carlin, GL; Grossmann, NC; Hajebrahimi, S; Jilch, S; Katayama, S; König, F; Laukhtina, E; Mori, K; Mostafaei, H; Pradere, B; Quhal, F; Rajwa, P; Roehrborn, CG; Salehi-Pourmehr, H; Sari Motlagh, R; Schuettfort, VM; Shariat, SF | 1 |
| Gomes, T; Herschorn, S; Jarvi, K; Juurlink, D; Matta, R; Nam, RK | 1 |
| Azab, SS; El Kafoury, M; El Sayed, O | 1 |
| Ciesielski, K; Dancz, C; Latack, K; Morocco, E; Nguyen, B | 1 |
| Dantas, LP; Forte, ARCC; Lessa, PHC; Lima, BC; Patrocínio, MCA; Sousa, CNS; Vasconcelos, EC; Vasconcelos, SMM; Vieira, RF | 1 |
| Chen, SF; Chuang, YC; Kuo, HC; Liao, CH; Wang, CC | 1 |
| Chyou, TY; Nishtala, PS | 1 |
| Berr, C; Droupy, S; Faillie, JL; Huguet, H; Malcher, MF; Mura, T; Serrand, C; Ziad, A | 1 |
| Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B | 1 |
| Chess-Williams, R; McDermott, C; Sellers, DJ; West, EG | 1 |
| Hsiao, SM; Lin, HH; Su, TC; Tu, FC; Wu, PC | 1 |
| Fang, KW; Li, P; Wang, G; Xu, R; Yang, TX | 1 |
| Bennett, T; Caldwell, P; Lai, E; Raman, G; Tunnicliffe, D | 1 |
| Liu, YQ; Tang, QL; Tao, RZ; Wu, J; Zhou, S | 1 |
| Brubaker, L; Halverson, T; Mueller, ER; Wolfe, AJ | 1 |
| Hara, H; Imamura, T; Ishizuka, O; Minagawa, T; Ogawa, T; Suzuki, A; Ueno, M | 1 |
| Blok, BFM; Dvorak, RV; Krhut, J; Peter, L; Rejchrt, M; Slovak, M; Zvara, P | 1 |
| Deo, A; Dhamala, JN; Pradhan, T; Yadav, SK | 1 |
| Chang, SH; Chen, DY; Chen, HX; Chou, EC; Huang, CM; Huang, CP; Huang, PH; Lan, JL; Wu, PC; Yeo, KJ | 1 |
| Hiren Prajapati, HP; Krunal Vishavadia, KV; Madhu Sharma, MS; Sandip Solanki, SS | 1 |
| Bellos, TC; Deliveliotis, CN; Kapsalos-Dedes, SG; Katsimperis, SN; Kostakopoulos, NA; Mitsogiannis, IC; Papatsoris, AG; Tzelves, LI; Varkarakis, IM | 1 |
| Badrawy, M; Hasan, MA; Mohamed, AR; Nour, IM | 1 |
| Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O | 1 |
| Cardozo, L; Chapple, CR; Choudhury, N; Cruz, F; Heesakkers, J; Herschorn, S; Siddiqui, E; Staskin, D; Stoelzel, M | 1 |
| Inoue, M; Yokoyama, T | 1 |
| Bae, WJ; Kim, SJ; Kim, SW | 1 |
| Kociszewski, J; Poleszak, E; Serefko, A; Szopa, A; Wiśniewski, R; Woźniak, A; Wróbel, A | 1 |
| Sahin, A; Urkmez, A; Yildirim, C; Yuksel, OH | 1 |
| Baka-Ostrowska, M; Bolong, D; Bosman, B; Dahler, E; Davies, LN; Franco, I; Hoebeke, P; Newgreen, D; Snijder, R; Stroosma, O; Vande Walle, J; Verheggen, F | 1 |
| Agema, M; Bosman, B; Snijder, R; Stroosma, O | 1 |
| Li, X; Liu, Q; Shi, R; Sun, S; Tang, Y; Xiang, J; Xiang, Y; Xiong, C; Yang, S; Zhou, Y | 1 |
| Nakanishi, S | 1 |
| Chen, W; Li, H; Li, N; Liu, Z; Lu, Y; Tian, F; Wang, X; Wen, Q | 1 |
| Coban, S; Demirci, H; Guzelsoy, M; Parmak Yener, N; Turkoglu, AR | 1 |
| Brucker, BM; Charlson, ER; Enemchukwu, E; Howard, J; Jericevic, D; Krupp, L; Pape, D; Peyronnet, B; Rosenblum, N; Rude, T; Zhovtis-Ryerson, L | 1 |
| Aschenbrenner, DS | 1 |
| El-Abd, AS; El-Abd, SA; Radwan, MH; Soliman, MG; Tawfik, AM | 1 |
| Bang, WJ; Cho, JS; Cho, ST; Hyun, JS; Joo, KJ; Kim, BH; Kim, JK; Lee, JB; Lee, YS; Oh, CY; Seo, YJ; Shim, M | 1 |
| Casal Beloy, T; Casal-Beloy, I; García-González, M; García-Novoa, MA; Somoza Argibay, I | 1 |
| Chae, C; Cheon, SH; Kim, SC; Kwon, T; Moon, KH; Park, M; Park, S; Yoon, JH | 1 |
| Fukuta, F; Ichihara, K; Kobayashi, K; Kyoda, Y; Masumori, N; Nofuji, S; Shinkai, N; Tanaka, T; Wanifuchi, A | 1 |
| Abou-Ramadan, AR; El-Abd, AS; El-Abd, S; El-Gamal, OM; Raheem, AA; Soliman, MG | 1 |
| Wang, S; Zhang, C; Zhang, Y; Zu, S | 1 |
| Duong, V; Iglesia, C; Iwamoto, A; Kudish, B; Pennycuff, J | 1 |
| Anvari, SO; Daneshpajooh, A; Dozchizadeh, S; Mirzaei, M; Teimorian, M | 1 |
| Panicker, JN; Richardson, K; Welk, B | 1 |
| Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Herschorn, S; Huang, M; MacDiarmid, S; Siddiqui, E; Stoelzel, M | 1 |
| Weissbart, SJ | 1 |
| Krivoborodov, GG; Tur, EI | 1 |
| Blok, BF; Scheepe, JR; Tijnagel, MJ | 1 |
| Abrams, P; Arlandis, S; Chapple, CR; Herschorn, S; Lee, KS; Mitcheson, D; Paireddy, A; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R | 1 |
| Athanasiou, S; Cambronero Santos, J; Chapple, CR; Drake, MJ; Esen, A; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Siddiqui, E; Stoelzel, M | 1 |
| Cardozo, L; Chapple, CR; Herschorn, S; Siddiqui, E; Snijder, R | 2 |
| Dandolu, V; Lua, LL; Pathak, P | 1 |
| Kaplan, SA | 1 |
| Besuyen, R; Bolduc, S; Bosman, B; Dahler, E; Hollestein-Havelaar, A; Newgreen, D; Rittig, S; Sawyer, W; Snijder, R | 1 |
| Bunyavejchevin, S | 1 |
| Devlin, N; Drake, MJ; Hakimi, Z; Herdman, M; Huang, M; MacDiarmid, S; Nazir, J; Pavesi, M; Siddiqui, E | 1 |
| Bourouina, R; Chartier-Kastler, E; Cornu, JN; Descazeaud, A | 1 |
| Falconer, C; Hakimi, Z; Herschorn, S; Kelleher, C; Mueller, ER; Paireddy, A; Ridder, A; Robinson, D; Staskin, D; Stoelzel, M; van Maanen, R; Wang, J | 1 |
| Van Batavia, J | 1 |
| Cho, WY; Choi, S; Kwon, T; Lee, JZ; Min, K; Moon, KH; Oh, TH | 1 |
| Henningsohn, L; Jacobsen, JL; Kilany, S; Svensson, M | 1 |
| Hodgkinson, L | 1 |
| Choudhury, N; Drake, MJ; Gibson, W; Huang, M; MacDiarmid, S; Siddiqui, E; Stölzel, M | 1 |
| Choi, WS; Chung, H; Kim, HG; Paick, SH; Park, HK; Yang, DY; Yang, SK | 1 |
| Pannek, J | 1 |
| Gainullina, Y; Kosilov, K; Kosilova, L; Kuzina, I; Kuznetsov, V; Loparev, S; Prokofyeva, A | 1 |
| Aballéa, S; Hakimi, Z; Kelleher, C; Maman, K; Mankowski, C; Nazir, J; Odeyemi, I | 1 |
| Apostolidis, A | 1 |
| Baltogiannis, D; Dimitriadis, F; Filiponi, M; Giannakis, J; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A | 1 |
| Benedetti Panici, P; D'Oria, O; Faiano, P; Muzii, L; Schiavi, MC; Zullo, MA | 1 |
| Casellato, S; Garofalo, F; Illiano, E; Maruccia, S; Morosetti, C; Rociola, W; Vecchioli-Scaldazza, C | 1 |
| Aboulhoda, BE; Ali, EN | 1 |
| Chang, HM; Chang, YC; Chen, HL; Chen, TC; Huang, WH; Juan, YS; Lee, HY; Pan, HF; Wang, YL; Wu, CM | 1 |
| Ablove, T; Bell, LN; Chappell, RJ; Liang, H; Toklu, HZ; Yale, SH | 1 |
| Chang, SL; Dupree, JM; Kirk, PS; Modi, PK; Singer, EA; Wang, Y | 1 |
| Kuo, HC; Wang, CC | 1 |
| Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Paireddy, A; Rechberger, T; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ | 1 |
| Staskin, DR | 1 |
| Apostolidis, A; Papathanasiou, A; Sakalis, V; Salpiggidis, G; Sfiggas, V; Vouros, I | 1 |
| Brucker, BM; Peyronnet, B | 1 |
| Kim, JH; Lee, SR; Park, BW | 1 |
| Islianti, PI; Matondang, FA; Rahardjo, HE; Syahputra, FA | 1 |
| Atici, A; Ecer, G; İyisoy, MS; Özkent, MS; Öztürk, A; Sönmez, MG | 1 |
| Cui, Y; Gao, Z; Li, Y; Wang, J; Wu, J; Yuan, H; Zhou, Z; Zhu, Z | 1 |
| Wein, AJ | 2 |
| Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 2 |
| Herbison, P; McKenzie, JE | 1 |
| Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Rechberger, T; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ | 1 |
| Cetinel, B; Dincer, M; Gultekin, MH; Guzelsoy, M; Onal, B; Turegun, FA | 1 |
| Gratzke, C; Siddiqui, E | 1 |
| De Wachter, S; Foley, S; Huang, M; Rees, J; Rosa Arias, J; Skoumal, R; Walters, C; Yavuz, Y | 1 |
| Almeida, FG; Bernardo, WM; Sacomani, CAR; Silvinato, A | 1 |
| Gao, Z; Zhou, Z | 1 |
| Wang, HT; Xia, M | 1 |
| Hansson, F; Kilany, S; Milsom, I; Schiotz, HA; Svensson, M | 1 |
| Chang, TC; Hsiao, SM; Lin, HH | 1 |
| Compion, G; Dale, M; Stow, B; Tretter, R; Wagg, A | 2 |
| Hsiao, SM; Kuo, HC; Lin, HH | 2 |
| Berouz, A; Ferrara, V; Giannubilo, W; Morosetti, C; Vecchioli-Scaldazza, C | 1 |
| Mauseth, SA; Skurtveit, S; Spigset, O | 1 |
| Abrams, P; Hart, WM; Munro, V; Nazir, J; Retsa, P | 1 |
| Braga, A; Cattoni, E; Cromi, A; Ghezzi, F; Salvatore, S; Serati, M; Siesto, G; Sorice, P; Uccella, S | 1 |
| Byun, SS; Kim, KH; Lee, JY; Lee, SH; Lee, SJ | 1 |
| Akino, H; Fujiuchi, Y; Fuse, H; Kitagawa, Y; Miyazawa, K; Namiki, M; Suzuki, K; Yokoyama, O | 1 |
| Arumi, D; Lizarraga, I; Miranda, P; Rejas, J; Sánchez-Ballester, F | 1 |
| Betz, D; Burger, M; Hampel, C; Vogel, M | 1 |
| Aguado-Jodar, A; Ibáñez-Nolla, J; Kvasz, M; Navarro-Artieda, R; Rejas, J; Ruiz-Torrejón, A; Sicras-Mainar, A | 1 |
| Braga, A; Ghezzi, F; Salvatore, S; Serati, M; Siesto, G; Sorice, P | 1 |
| Gotoh, M; Kobayashi, T; Sogabe, K | 1 |
| Walton, A | 1 |
| An, R; Guan, Z; Guo, H; He, D; Huang, J; Huang, Y; Kong, C; Li, H; Liao, L; Liu, M; Shen, Z; Song, B; Song, X; Sun, Y; Wang, D; Wang, J; Wang, X; Wen, J; Xiao, J; Yang, Y; Ye, Z; Zeng, P; Zhang, X; Zhao, X; Zheng, S | 1 |
| Guo, KC; Huo, LZ; Jing, HG; Luan, XH; Shi, BK; Wang, TC; Yuan, SX | 1 |
| Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R | 1 |
| Aguado-Jodar, A; Navarro-Artieda, R; Rejas-Gutiérrez, J; Ruíz-Torrejón, A; Sicras-Mainar, A | 1 |
| Hart, WM; Nazir, J | 1 |
| Gao, ZW; Li, HB; Ren, XQ; Shang, YF; Shao, CS; Xiao, F; Xin, SY; Zhang, JG; Zhang, W | 1 |
| Cao, Z; Guo, F; Pan, A; Peng, S; Sun, Y; Wang, H; Wang, L; Wei, R; Xu, C; Zhang, C; Zhang, Z | 1 |
| Arslan, U; Dolen, I; Hekimoglu, E; Petricli, IS; Sekeroglu, MA; Tasci, Y | 1 |
| Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Su, TC | 1 |
| Adiloğlu, AK; Arslan, H; Aydın, A; Aydoğmuş, Y; Şahin, H; Sunay, M | 1 |
| Chou, EC; Chuang, YC; Huang, ST; Hung, MJ; Kuo, HC; Meng, E; Yen, TW | 1 |
| Kosilov, KV; Kosilova, LV; Krasnykh, MA; Loparev, SA | 1 |
| Chapple, C; Drake, MJ; Drogendijk, T; Klaver, M; Oelke, M; Sokol, R; Traudtner, K; Van Kerrebroeck, P | 1 |
| Ivanovskaya, M; Kosilov, K; Kosilova, L; Loparev, S | 1 |
| Andersson, KE | 1 |
| Ivanovskaya, MA; Kosilov, KV; Kosilova, LV; Loparev, SA | 2 |
| Doo, SW; Kim, JH; Lee, SW; Yang, HJ; Yang, WJ; Yun, JH | 1 |
| Chang, TC; Chen, CH; Hsiao, SM; Liao, SC; Lin, HH | 1 |
| Chung, BH; Hong, S; Kim, CS; Kim, DK; Kim, JC; Lee, JG; Lee, KS; Lee, YS; Park, CH; Park, JK | 1 |
| Chung, BH; Hong, SJ; Kim, CS; Kim, DK; Kim, JC; Lee, HN; Lee, JG; Lee, KS; Park, CH; Park, JK | 1 |
| Li, J; Li, P; Liu, B; Wang, Y; Wu, Y | 1 |
| Choo, MS; Han, JY; Kim, DY; Kwon, DD; Lee, JG; Lee, JZ; Lee, KS; Na, YG; Park, CH; Park, WH | 1 |
| De Nunzio, C; Presicce, F; Puccini, F; Tubaro, A | 1 |
| Cheon, SY; Cho, SY; Choi, JB; Choo, MS; Chun, JY; Kim, JC; Kim, JH; Lee, KS; Oh, SJ; Park, J; Seo, JT; Song, M | 1 |
| Huang, W; Zhang, Y; Zhou, X; Zong, H | 1 |
| Borodulina, IV; Kadykov, AS; Kravchenko, MA; Popov, SV; Shvarts, PG; Vinarov, AZ | 1 |
| Hagiwara, M; Hasegawa, M; Ishioka, K; Kikuchi, E; Maeda, T; Miyajima, A; Miyazaki, Y; Oya, M; Shinojima, T | 1 |
| Evatt, M; Jahan, I; Ordorica, R; Salemi, JL; Shaw, JD; Singer, C; Sullivan, KL; Vaughan, CP; Zesiewicz, TA | 1 |
| Kagan, OF; Kheĭfets, VKh; Sosnovskiĭ, SO | 2 |
| Abrams, P; Kay, R; Martina, R; Ridder, A; van Maanen, R | 1 |
| Cruz, F | 2 |
| Compion, G; Khullar, V; Oelke, M; Robinson, D; Stow, B; Tretter, R; Tubaro, A; Wijkstra, H | 1 |
| Cekmen, MB; Ciftci, S; Ozkurkcugil, C; Ustuner, M; Yavuz, U; Yilmaz, H; Yuksekkaya, M | 1 |
| Arslan, U; Dolen, I; Hekimoglu, E; Sekeroglu, MA; Tasci, Y | 1 |
| Cornu, JN | 2 |
| de Greef-van der Sandt, I; Dorrepaal, C; Martina, R; Newgreen, D; Ridder, A; Schaddelee, M; van Maanen, R | 1 |
| Avcı, F; Aytaç-Tohma, Y; Bakacak, M; Çoşkun, B; Efe, E; Ercan, Ö; Köstü, B | 1 |
| Coll-de Tuero, G; Navarro-Artieda, R; Ruiz-Torrejón, A; Sáez-Zafra, M; Sicras-Mainar, A | 2 |
| Alkis, O; Aybek, H; Aybek, Z; Toktas, C; Zumrutbas, AE | 1 |
| Agarwal, M; Amarenco, G; Compion, G; De Ridder, D; Del Popolo, G; Sutory, M; Tretter, R; Zachoval, R | 1 |
| Bai, WP; Cheng, XX; Gong, MY; Huang, YL; Jiang, F; Li, HF; Li, X; Tong, XW; Wang, JJ; Xu, HC; Xu, T; Xu, XX; Zhu, L | 1 |
| Berner, T; Castro-Diaz, D; Kelleher, C; Nitti, VW; Siddiqui, E; Wagg, A | 1 |
| Athanasiou, S; Cambronero, J; Chapple, C; Drake, MJ; Esen, AA; Herholdt, C; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Saleem, T; Siddiqui, E; Stölzel, M | 1 |
| Rechberger, T; Wróbel, A | 1 |
| Bae, SR; Cho, SY; Han, CH; Hur, KJ; Kim, HW; Kim, SH; Lee, KW; Lee, YS; Park, BH | 1 |
| Choo, MS; Kim, TH; Kwon, DD; Lee, JG; Lee, JZ; Lee, KS; Na, YG; Park, CH; Park, JH; Park, WH; You, HW | 1 |
| Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Grise, P; Hakimi, Z; Hemsted, C; Herschorn, S; Huang, M; MacDiarmid, S; Nazir, J; Saleem, T; Siddiqui, E; Stölzel, M | 1 |
| Morosetti, C; Vecchioli Scaldazza, C | 1 |
| Cho, SY; Lee, SB; Paick, JS; Park, S; Son, H | 1 |
| Alcántara-Montero, A | 1 |
| Sidaway, P | 1 |
| Griebling, TL | 1 |
| Aydogmus, Y; Ebiloglu, T; Goktas, MT; Gundogan, FC; Ulas, UH; Uzun, S | 1 |
| Imamura, T; Ishizuka, O; Minagawa, T; Nagai, T; Nakazawa, M; Ogawa, T; Saito, T; Suzuki, T; Yokoyama, H | 1 |
| Abrams, P; Kay, R; Kelleher, C; Martan, A; Mincik, I; Newgreen, D; Paireddy, A; Ridder, A; Staskin, D; van Maanen, R | 1 |
| Masumori, N; Tanaka, Y; Tanuma, Y | 1 |
| Ito, N; Kamiyama, Y; Kanamaru, S; Kawakita, M; Matsumoto, K; Muguruma, K; Shirahase, T; Takahashi, T; Tsukazaki, H; Tsunemori, H; Utsunomiya, N | 1 |
| Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY | 1 |
| Besuyen, R; Bolduc, S; Bosman, B; Dahler, E; Hollestein-Havelaar, A; Newgreen, D; Rittig, S; Sawyer, W | 1 |
| Choi, IS; Park, JK; Shin, YS; You, JH; Zhang, LT; Zhao, C | 1 |
| Coban, S; Demirbas, M; Demirci, H; Guzelsoy, M; Turkoglu, AR; Yener, NP | 1 |
| Kinjo, M; Nutahara, K; Sekiguchi, Y; Yoshimura, Y | 1 |
| Blais, AS; Bolduc, S; Genois, L; Moore, K; Morin, F; Nadeau, G | 1 |
| Arumi, D; García-Mediero, JM; Lizarraga, I; Sánchez-Ballester, F; Sobrón-Bustamante, M | 1 |
| Cho, WY; Chung, JM; Kang, DI; Lee, SD; Park, S; Ryu, DS | 1 |
| Kosilov, K; Kuzina, I; Lobodenko, A; Loparev, S; Shakirova, O; Zhuravskaya, N | 1 |
| Betz, D; Burger, M; Hampel, C; Nowak, C; Vogel, M | 1 |
| Balingit, JC; Chua, ME; Esmeňa, EB; Morales, ML; See, MC | 1 |
| Abrams, S; Aliotta, P; Everaert, K; Herschorn, S; Kohan, A; Lam, W; McCammon, K; Sriram, R | 1 |
| Kirby, J; Obloza, A; Toozs-Hobson, P; Yates, D | 1 |
| Alekseeva, AV; Fedorenko, VN; Shelyakina, OV; Vilgelmi, IA; Yarin, GY | 1 |
| Ahamed, AA; Lim, V; Masten Singh, PK; Naidu, P; Nalliah, S; Wg, P | 1 |
| Bolodeoku, J; Khullar, V; Mundy, A; Odeyemi, I; Speakman, M | 1 |
| Widhalm, S | 1 |
| Capo, JP; Forero-Schwanhaeuser, S; Pelman, RS | 1 |
| Costa, AM; Galatioto, GP; Gravina, GL; Martella, O; Ronchi, P; Vicentini, C | 1 |
| Al, MJ; Hakkaart, L; Phillips, R; Verboom, P | 1 |
| Asajima, H; Matsushima, S; Saito, N; Saito, T; Sekiguchi, Y | 1 |
| Arañó, P; Bolodeoku, J; Cardozo, L; Dewilde, L; Drogendijk, T; Hessdörfer, E; Milani, R; Slack, M; Wright, M | 1 |
| Andoh, M; Fakhoury, A; Forero-Schwanhaeuser, S; Karram, MM; Serels, SR; Toglia, MR | 1 |
| Capo', JP; Chancellor, MB; Forero-Schwanhaeuser, S; Karram, M; Kobashi, K; Laramée, C; Nandy, I; Seifeldin, R; Siami, P; Snyder, JA; Whitmore, K; Zinner, N | 1 |
| Burcher, E; Chandran, JJ; Christopoulos, A; Mansfield, KJ; Millard, RJ; Mitchelson, FJ; Vaux, KJ | 1 |
| Choo, MS; Jung, HC; Kim, HJ; Kim, JC; Kim, YH; Lee, JB; Lee, JG; Lee, JZ; Lee, KS; Na, YG; Paick, JS; Seo, JT | 1 |
| Fabisovský, M; Havránek, O; Krhut, J; Míka, D; Valis, P | 1 |
| Schaefer, W | 1 |
| Duggan, P; Wong, C | 1 |
| Hoffstetter, S; Leong, FC | 1 |
| Forero-Schwanhaeuser, S; Siami, P; Swift, SE | 1 |
| Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J | 1 |
| Brenes, FJ; Chapple, CR; Rosenberg, MT | 1 |
| Andoh, M; Dmochowski, R; Forero-Schwanhaeuser, S; Sand, PK; Steers, WD | 1 |
| Iannazzo, S; Pradelli, L | 1 |
| Altman, D; Falconer, C; Granath, F; Mattiasson, A | 1 |
| De Caestecker, K; De Pooter, J; Dehoorne, J; Hoebeke, P; Raes, A; Van Laecke, E; Vande Walle, J | 1 |
| Bolodeoku, J; Masala, A; Mattiasson, A; Morton, R | 1 |
| Andoh, M; Forero-Schwanhaeuser, S; Karram, MM; Laramée, C; Nandy, IM; Seifeldin, R; Serels, SR; Toglia, MR | 1 |
| Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K | 2 |
| Forero-Schwanhaeuser, S; He, W; Marshall, TS; Mitcheson, HD; Samuels, TA; Vardy, MD; Wegenke, JD | 1 |
| Andoh, M; Forero-Schwanhaeuser, S; Gittelman, M; Goldfischer, ER; Kaplan, SA; Steers, WD | 1 |
| Marshall, T; Noe, L; Rasouliyan, L; Runken, MC; Seifeldin, R; Zinner, N | 1 |
| Cardozo, L; Sidhu, M; Thorpe, A; Warner, J | 1 |
| Miyata, K; Ohtake, A; Sasamata, M; Sato, S | 1 |
| Wyndaele, JJ | 1 |
| Barkin, J; Carlson, K; Drutz, H; Egerdie, B; Gajewski, JB; Herschorn, S; Paradiso-Hardy, F; Pommerville, P; Radomski, S; Schulz, J; Stothers, L | 1 |
| Andoh, M; Appell, RA; Fakhoury, A; Hussain, IF; Ostergard, DR; Toglia, MR | 1 |
| Santos, JC; Telo, ER | 1 |
| Masumori, N; Tanaka, Y; Tsukamoto, T | 1 |
| Herschorn, S; Piwko, C; Vicente, C | 1 |
| Forero-Schwanhaeuser, S; He, W; Serels, SR; Toglia, MR | 1 |
| Bolduc, S; Hamel, M; Lamontagne, P; Lebel, S; Moore, K; Nadeau, G | 1 |
| Chernev, T; Dimitrov, R; Doganov, N; Popov, E; Slavov, Ch; Slavov, S | 1 |
| Grinta, R; Vecchioli-Scaldazza, C | 1 |
| Chang, TC; Ho, CH; Huang, KH; Lin, HH; Liu, SP; Yu, HJ | 1 |
| Barkin, J; Carlson, K; Corcos, J; Drutz, H; Egerdie, B; Gajewski, J; Herschorn, S; Hirshberg, E; Pommerville, P; Radomski, S; Schulz, J; Stothers, L | 1 |
| Crosby, RD; Marshall, TS; Mathias, SD | 1 |
| Capo', JP; Forero-Schwanhaeuser, S; He, W; Lucente, V | 1 |
| de la Rosette, JJ; Michel, MC; Oelke, M; Vogel, M | 1 |
| Bungay, PJ; Callegari, E; Fenner, KS; Kay, GG; Kempshall, S; LaPerle, JL; Malhotra, B; Michel, MC; Webster, R | 1 |
| Schröder, A; Thüroff, JW | 1 |
| Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY; Yu, HJ | 1 |
| Gotoh, M; Ishizuka, O; Itoh, N; Kakizaki, H; Okada, H; Ozono, S; Seki, N; Sugiyama, T; Yamada, S; Yamaguchi, O; Yokota, T; Yokoyama, O; Yoshida, M | 1 |
| Kalchthaler, M; Mühlich, S; Rothe, P | 2 |
| Gotoh, M; Homma, Y; Kakizaki, H; Nishizawa, O; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 1 |
| Fukuhara, S; Matsuoka, Y; Miyagawa, Y; Nakayama, J; Nonomura, N; Takao, T; Tsujimura, A; Yamamoto, K | 1 |
| Kuo, HC; Lin, H; Liu, HT | 1 |
| Abrams, P; Chapple, CR; Jünemann, KP; Sharpe, S | 1 |
| Brubaker, L; Durazo-Arivzu, RA; Fitzgerald, MP; Kenton, K; Lowenstein, L; Mueller, ER; Sabo, E | 1 |
| Akino, H; Aoki, Y; Ito, H; Nagase, K; Tanase, K; Yokoyama, O | 1 |
| Cody, JD; Ellis, G; Hay-Smith, EJ; Herbison, GP; Madhuvrata, P | 1 |
| Han, P; Liu, L; Luo, D; Shen, H; Wei, Q | 1 |
| Cho, KS; Chung, JH; Ha, US; Ham, WS; Han, JH; Kang, DH; Lee, JY; Lee, SH; Lee, SW; Park, J; Yoo, TK | 1 |
| Banović, M; But, I; Goldstajn, MS; Oresković, S | 1 |
| Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL | 1 |
| Ammann, LP; Bukofzer, S; Haas, GP; He, W; Janning, SW; Zinner, NR | 1 |
| Fukumoto, K; Hara, R; Koide, T; Miyaji, Y; Nagai, A; Yokoyama, T | 1 |
| Krebs, J; Pannek, J | 1 |
| Amarenco, G; Cardozo, L; Compion, G; Drogendijk, T; Mikulas, J; Pushkar, D; Wright, M | 1 |
| Jiang, XZ; Xu, C; Xu, ZS; Zhang, NZ; Zhao, HF | 1 |
| But, I; Goldstajn, MS; Oresković, S | 1 |
| Cardozo, L; Kelleher, C; Kobashi, K; Lucente, V | 1 |
| Cardozo, L; Castro-Diaz, D; Gittelman, M; Huang, M; Ridder, A | 1 |
| Goepel, M | 1 |
| Cardozo, L; Chapple, CR; Govier, FE; Steers, WD | 1 |
| Kreder, KJ | 1 |
| Hegde, SS; Michel, MC | 1 |
| Maniscalco, M; Singh-Franco, D; Torres-Colón, R; Wolowich, WR | 1 |
| Drinka, PJ | 1 |
| Chapple, CR | 1 |
| Brubaker, L; FitzGerald, MP | 1 |
| Ikeda, K; Miyata, K; Ohtake, A; Sasamata, M; Sato, S | 1 |
| Hatanaka, T; Miyata, K; Noguchi, Y; Ohtake, A; Okutsu, H; Saitoh, C; Sasamata, M; Sato, S; Suzuki, M; Ukai, M; Yuyama, H | 1 |
| Colaço, J; Gonçalves, V; Metello, J; Nogueira, B; Retto, H; Torgal, M; Vieira, A | 1 |
| Andoh, M; Garely, AD; Kaufman, JM; Sand, PK; Smith, N | 1 |
| Kelleher, C; Payne, CK | 1 |
| Combest, W; Kosier, JH; Newton, M | 1 |
| Cardozo, L; Cartwright, R; Robinson, D; Vella, M | 1 |
| Adekunle, R; Bilal, S; Fishwick, K; Khunda, A | 1 |
| Garely, AD; Lucente, V; Smith, N; Vapnek, J | 1 |
| Chapple, C | 1 |
| Burks, D; Garely, AD; Mallett, V; Smith, N | 1 |
| Bertozzi, R; Cipriani, S; Colli, E; Meschia, M; Montorsi, F; Olivieri, L; Parazzini, F | 1 |
| Bolodeoku, J; Chapple, CR; Fianu-Jonsson, A; Indig, M; Khullar, V; Mistry, A; Rosa, J; Scarpa, RM; Wright, DM | 1 |
| Colli, E; Digesu, GA; Olivieri, L | 1 |
| Gotoh, M; Ishizuka, O; Itoh, N; Kakizaki, H; Marui, E; Okada, H; Ozono, S; Seki, N; Sugiyama, T; Yamaguchi, O; Yokota, T; Yoshida, M | 1 |
| Cardozo, L; Drogendijk, TE; Huang, AM; Kuzmin, I; Lisec, M; Milard, R; Van Vierssen Trip, O | 1 |
| Capo', JP; Fakhoury, A; Forero-Schwanhaeuser, S; Laramée, C; Lucente, V | 1 |
| Hilas, O; Lam, S | 1 |
| Gach, JE; Shalders, K | 1 |
| Marshall, T; Noe, L; Rasouliyan, L; Seifeldin, R; Zinner, N | 1 |
| Feldman, LS; Pemmaraju, N | 1 |
46 review(s) available for solifenacin succinate and Urinary Bladder, Overactive
| Article | Year |
|---|---|
History and current trends in the treatment of idiopathic overactive bladder.
Topics: Benzhydryl Compounds; Humans; Muscarinic Antagonists; Quality of Life; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.
Topics: Benzhydryl Compounds; Humans; Muscarinic Antagonists; Network Meta-Analysis; Receptors, Adrenergic; Solifenacin Succinate; Urinary Bladder, Overactive; Urinary Incontinence | 2022 |
Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?
Topics: Aged; Cognitive Dysfunction; Dementia; Humans; Solifenacin Succinate; Urinary Bladder; Urinary Bladder, Overactive | 2022 |
Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Botulinum Toxins, Type A; Humans; Muscarinic Antagonists; Network Meta-Analysis; Solifenacin Succinate; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics | 2022 |
Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review.
Topics: Adolescent; Child; Cholinergic Antagonists; Constipation; Humans; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2023 |
Ureteral Stent-Related Symptoms and Pharmacotherapy: A Brief Narrative Review.
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Humans; Solifenacin Succinate; Stents; Urinary Bladder, Overactive | 2023 |
A systematic review of neurocognitive dysfunction with overactive bladder medications.
Topics: Aged; Cognitive Dysfunction; Humans; Muscarinic Antagonists; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2021 |
The cognitive effect of anticholinergics for patients with overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cognition; Cognitive Dysfunction; Dementia; Humans; Mandelic Acids; Prodromal Symptoms; Pyrrolidines; Risk Assessment; Risk Factors; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2021 |
[Comprehensive pharmacologic management of overactive bladder].
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Combinations; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Sulfonamides; Tamsulosin; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive | 2017 |
[Overactive bladder-which treatment when?]
Topics: Behavior Therapy; Botulinum Toxins, Type A; Diagnosis, Differential; Electric Stimulation Therapy; Female; Gabapentin; Humans; Injections, Intramuscular; Lumbosacral Plexus; Male; Muscarinic Antagonists; Patient Preference; Physical Therapy Modalities; Solifenacin Succinate; Tadalafil; Urinary Bladder; Urinary Bladder, Overactive | 2017 |
Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Benzilates; Humans; Mandelic Acids; Muscarinic Antagonists; Network Meta-Analysis; Solifenacin Succinate; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2018 |
Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents | 2018 |
Management of Overactive Bladder Symptoms After Radical Prostatectomy.
Topics: Botulinum Toxins, Type A; Humans; Male; Muscarinic Antagonists; Neuromuscular Agents; Postoperative Complications; Prostate; Prostatectomy; Solifenacin Succinate; Tolterodine Tartrate; Urethral Stricture; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urinary Incontinence, Stress | 2018 |
Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
Topics: Acetanilides; Humans; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2019 |
Which anticholinergic is best for people with overactive bladders? A network meta-analysis.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Humans; Imidazoles; Mandelic Acids; Network Meta-Analysis; Pyrrolidines; Solifenacin Succinate; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2019 |
Comparisons of Therapeutic Efficacy and Safety of Solifenacin versus Tolterodine in Patients with Overactive Bladder: A Meta-Analysis.
Topics: Humans; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2019 |
The use of pharmacotherapy for male patients with urgency and stress incontinence.
Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urinary Incontinence, Urge; Urological Agents | 2014 |
[Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes].
Topics: Benzhydryl Compounds; Constipation; Cresols; Humans; Phenylpropanolamine; Quinuclidines; Safety; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Xerostomia | 2014 |
Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
Topics: Adult; Benzilates; Constipation; Humans; Imidazoles; Randomized Controlled Trials as Topic; Solifenacin Succinate; Urinary Bladder, Overactive; Urological Agents; Xerostomia | 2015 |
[Current pharmacotherapy of overactive bladder in neurological patients].
Topics: Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urination; Urological Agents | 2014 |
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Topics: Acetanilides; Administration, Oral; Adrenergic beta-Antagonists; Aged; Benzhydryl Compounds; Blood Pressure; Clinical Trials as Topic; Constipation; Female; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Retrospective Studies; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2016 |
Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?
Topics: Age Factors; Body Mass Index; Female; Humans; Male; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Sex Factors; Solifenacin Succinate; Urinary Bladder, Overactive; Urinary Incontinence | 2017 |
Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis.
Topics: Dose-Response Relationship, Drug; Female; Humans; Mandelic Acids; Randomized Controlled Trials as Topic; Solifenacin Succinate; Urinary Bladder, Overactive; Urological Agents; Women's Health | 2017 |
Solifenacin at 3 years: a review of efficacy and safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
Solifenacin succinate for the treatment of overactive bladder.
Topics: Animals; Clinical Trials as Topic; Female; Humans; Male; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.
Topics: Benzofurans; Drug Administration Schedule; Humans; Mandelic Acids; Multicenter Studies as Topic; Muscarinic Antagonists; Patient Satisfaction; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgen
Topics: Adenosine Triphosphate; Afferent Pathways; Animals; Disease Models, Animal; Humans; Muscarinic Antagonists; Muscle Contraction; Quinuclidines; Rats; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2010 |
Solifenacin: scientific evidence in the treatment of overactive bladder.
Topics: Clinical Trials as Topic; Humans; Muscarinic Antagonists; Quality of Life; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2010 |
New strategies for medical management of overactive bladder in children.
Topics: Benzhydryl Compounds; Benzilates; Botulinum Toxins; Child; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quinuclidines; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination | 2010 |
Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome.
Topics: Endpoint Determination; Female; Humans; Male; Muscarinic Antagonists; Outcome Assessment, Health Care; Prevalence; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Young Adult | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2012 |
Solifenacin for overactive bladder: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; Humans; Imidazoles; Mandelic Acids; Muscarinic Antagonists; Nocturia; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2012 |
[Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis].
Topics: Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Solifenacin significantly improves all symptoms of overactive bladder syndrome.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2006 |
Solifenacin.
Topics: Clinical Trials as Topic; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2006 |
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Parasympatholytics; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
Solifenacin succinate for the treatment of symptoms of overactive bladder.
Topics: Clinical Trials as Topic; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2006 |
Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.
Topics: Dose-Response Relationship, Drug; Female; Humans; Male; Molecular Structure; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2006 |
[Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].
Topics: Animals; Clinical Trials as Topic; Humans; Muscarinic Antagonists; Muscle, Smooth; Quinuclidines; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder; Urinary Bladder, Overactive; Urination | 2006 |
Redefining response in overactive bladder syndrome.
Topics: Double-Blind Method; Humans; Multicenter Studies as Topic; Muscarinic Antagonists; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
New developments in the treatment of urinary incontinence.
Topics: Administration, Cutaneous; Adrenergic Uptake Inhibitors; Benzofurans; Drug Therapy, Combination; Duloxetine Hydrochloride; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrrolidines; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiophenes; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress | 2006 |
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Topics: Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination | 2007 |
Update on drugs for overactive bladder syndrome.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Overactive bladder treatments in early phase clinical trials.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drugs, Investigational; Guanidines; Humans; Mice; Muscarinic Antagonists; Quinuclidines; Receptors, Muscarinic; Sensitivity and Specificity; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2007 |
Pharmacologic management of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
120 trial(s) available for solifenacin succinate and Urinary Bladder, Overactive
| Article | Year |
|---|---|
Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study.
Topics: Acetanilides; Aged; Aged, 80 and over; Central Nervous System Diseases; Cognition; Cohort Studies; Drug Therapy, Combination; Humans; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2022 |
Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial.
Topics: Acetanilides; Female; Humans; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Vascular Stiffness | 2022 |
Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study.
Topics: Acetanilides; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Prospective Studies; Quality of Life; Solifenacin Succinate; Stents; Treatment Outcome; Urinary Bladder, Overactive | 2022 |
Prospective, Randomized, Multicenter Trial of Peroneal Electrical Transcutaneous Neuromodulation vs Solifenacin in Treatment-naïve Patients With Overactive Bladder.
Topics: Female; Humans; Muscarinic Antagonists; Prospective Studies; Quality of Life; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2023 |
Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial.
Topics: Acetanilides; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Sjogren's Syndrome; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2023 |
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
Topics: Acetanilides; Aged; Aged, 80 and over; Benzilates; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Databases, Factual; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Humans; Middle Aged; Prospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Visual Analog Scale | 2019 |
Influence of solifenacin on the improvement of storage symptoms in the early period after photoselective vaporization of the prostate.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Postoperative Complications; Solifenacin Succinate; Time Factors; Urinary Bladder, Overactive | 2019 |
Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial.
Topics: Acetanilides; Adult; Drug Therapy, Combination; Humans; Middle Aged; Quality of Life; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Catheters; Urological Agents | 2020 |
Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.
Topics: Adult; Child; Humans; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence | 2020 |
Relationship between mean volume voided and incontinence in children with overactive bladder treated with solifenacin: post hoc analysis of a phase 3 randomised clinical trial.
Topics: Child; Double-Blind Method; Humans; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2020 |
Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol.
Topics: Adolescent; Adult; Aged; Electroacupuncture; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Surveys and Questionnaires; Urinary Bladder, Overactive; Young Adult | 2020 |
Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study.
Topics: Acetanilides; Adult; Constipation; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Patient Reported Outcome Measures; Prospective Studies; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
Topics: Acetanilides; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Single-Blind Method; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Age Factors; Child; Child, Preschool; Egypt; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2021 |
Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Antagonists; Prognosis; Prospective Studies; Solifenacin Succinate; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactive; Young Adult | 2021 |
Evaluation of the Clinical Efficacy and Complications of Duloxetine in Comparison to Solifenacin in the Treatment of Overactive Bladder Disease in Women: A Randomized Clinical Trial.
Topics: Duloxetine Hydrochloride; Female; Humans; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Topics: Acetanilides; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Internationality; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Risk Assessment; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2017 |
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2017 |
Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder.
Topics: Adolescent; Child; Double-Blind Method; Humans; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2017 |
Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2017 |
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Topics: Acetanilides; Double-Blind Method; Drug Therapy, Combination; Humans; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Visual Analog Scale | 2018 |
Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality.
Topics: Age Factors; Aged; Body Mass Index; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nocturia; Severity of Illness Index; Sex Factors; Sleep; Solifenacin Succinate; Time Factors; Urinary Bladder, Overactive | 2017 |
Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Topics: Acetanilides; Aged; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2017 |
Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.
Topics: Acetylcholine; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Xerostomia; Young Adult | 2019 |
A randomized, multicenter, controlled study, comparing efficacy and safety of a new complementary and alternative medicine (CAM) versus Solifenacin Succinate in women with overactive bladder syndrome.
Topics: Adult; Aged; Complementary Therapies; Female; Humans; Middle Aged; Prospective Studies; Solifenacin Succinate; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination; Urological Agents | 2017 |
The effect of solifenacin on postvoid dribbling in women: results of a randomized, double-blind placebo-controlled trial.
Topics: Child; Double-Blind Method; Female; Humans; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2018 |
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Topics: Acetanilides; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Symptom Assessment; Thiazoles; Time; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2018 |
Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Greece; Humans; Male; Middle Aged; Muscarinic Antagonists; Organ Size; Pilot Projects; Prospective Studies; Prostate; Prostatic Hyperplasia; Severity of Illness Index; Solifenacin Succinate; Tamsulosin; Urinary Bladder, Overactive; Urination | 2018 |
Efficacy of Additional Solifenacin Succinate Therapy for Storage Symptoms in Females with Uncomplicated Lower Urinary Tract Infection: The SOLUTION Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Middle Aged; Muscarinic Antagonists; Quality of Life; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Tract Infections | 2018 |
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Benzilates; Blood Pressure; Constipation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Nasopharyngitis; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Xerostomia | 2019 |
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult | 2019 |
Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Topics: Adult; Aged; Benzhydryl Compounds; Benzilates; Benzofurans; Blood Pressure; Female; Heart Rate; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Nortropanes; Prospective Studies; Pyrrolidines; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study.
Topics: Aged; Drug Administration Schedule; Female; Humans; Middle Aged; Muscarinic Antagonists; Recurrence; Retreatment; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Humans; Middle Aged; Patient Satisfaction; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tibial Nerve; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination; Urological Agents | 2013 |
Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2014 |
[A combination of solifenacin succinate and naftopidil in the treatment of female overactive bladder].
Topics: Adult; Drug Therapy, Combination; Female; Humans; Middle Aged; Muscarinic Antagonists; Naphthalenes; Piperazines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Young Adult | 2013 |
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Drug Combinations; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents | 2015 |
[Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Topics: Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors.
Topics: Cystectomy; Cystitis; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Remission Induction; Single-Blind Method; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urination Disorders | 2014 |
Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
Topics: Acupuncture Therapy; Adolescent; Adult; Biomarkers; Female; Humans; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Quality of Life; Quinuclidines; Recovery of Function; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Turkey; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents; Young Adult | 2014 |
[Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
Topics: Aged; Benzhydryl Compounds; Benzilates; Cresols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2014 |
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Chemistry, Pharmaceutical; Double-Blind Method; Drug Combinations; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Prostatic Hyperplasia; Solifenacin Succinate; Sulfonamides; Tablets; Tamsulosin; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Retention; Urodynamics; Urological Agents | 2015 |
Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
Topics: Age Factors; Aged; Benzilates; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Nortropanes; Quinuclidines; Russia; Severity of Illness Index; Sex Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2014 |
Can we decide the optimal initial treatment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective, open-label study.
Topics: Aged; Decision Making; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostate; Quality of Life; Quinuclidines; Republic of Korea; Solifenacin Succinate; Sulfonamides; Symptom Assessment; Tamsulosin; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2014 |
Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.
Topics: Female; Humans; Linear Models; Middle Aged; Muscarinic Antagonists; Psychometrics; Quality of Life; Solifenacin Succinate; Surveys and Questionnaires; Tolterodine Tartrate; Urinary Bladder, Overactive; Women's Health | 2014 |
Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Solifenacin Succinate; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive; Urological Agents | 2015 |
A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Furosemide; Humans; Hypertension; Inpatients; Longitudinal Studies; Male; Prospective Studies; Quinuclidines; Risk Factors; Russia; Sodium Potassium Chloride Symporter Inhibitors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2014 |
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2015 |
Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.
Topics: Double-Blind Method; Female; Humans; Male; Parkinson Disease; Pilot Projects; Solifenacin Succinate; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2015 |
[Peculiarities of clinical course, diagnostics and treatment of overactive bladder in men older than 60 years].
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Prostatitis; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2014 |
A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OAB.
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2016 |
Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study.
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Middle Aged; Solifenacin Succinate; Treatment Outcome; Ultrasonography; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents | 2016 |
Ocular surface changes following oral anticholinergic use for overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Eye; Female; Humans; Middle Aged; Solifenacin Succinate; Urinary Bladder, Overactive | 2016 |
A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Decision Support Techniques; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Risk Assessment; Risk Factors; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
Comparison of solifenacin and fesoterodine in treatment of overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2015 |
Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Quality of Life; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics; Urological Agents; Young Adult | 2017 |
Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study.
Topics: Administration, Intravaginal; Aged; China; Estrogens; Female; Humans; Middle Aged; Muscarinic Antagonists; Postmenopause; Quality of Life; Solifenacin Succinate; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2016 |
Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
Topics: Adrenergic alpha-Antagonists; Aged; Cholinergic Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Solifenacin Succinate; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2017 |
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics; Young Adult | 2016 |
Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2016 |
Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Double-Blind Method; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2016 |
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYM
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2017 |
[A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cross-Over Studies; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Solifenacin Succinate; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial.
Topics: Adolescent; Child; Child, Preschool; Constipation; Double-Blind Method; Female; Humans; Male; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Xerostomia | 2017 |
Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Quality of Life; Solifenacin Succinate; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
Topics: Acetanilides; Drug Substitution; Female; Humans; Long-Term Care; Postmenopause; Prospective Studies; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.
Topics: Asian People; Child; Child, Preschool; Drug Tolerance; Fatigue; Female; Humans; Male; Prospective Studies; Republic of Korea; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents; Xerostomia | 2017 |
The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.
Topics: Aged; Benzilates; Diagnostic Self Evaluation; Drug Therapy, Combination; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Nortropanes; Prostatic Hyperplasia; Self-Assessment; Solifenacin Succinate; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urinary Bladder, Overactive | 2017 |
Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Administration Schedule; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2018 |
The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
Topics: Aged; Botulinum Toxins, Type A; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuromuscular Agents; Quality of Life; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2017 |
A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Double-Blind Method; Humans; Markov Chains; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Muscle Contraction; Perception; Prospective Studies; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2009 |
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination Disorders; Urodynamics | 2008 |
Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Urinary Bladder, Overactive; Urination | 2009 |
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Topics: Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Patient Satisfaction; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urinary Retention | 2008 |
[Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV].
Topics: Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2008 |
Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Topics: Adult; Aged; Cholinergic Antagonists; Female; Humans; Mandelic Acids; Middle Aged; Nocturia; Pilot Projects; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Failure; Urinary Bladder, Overactive | 2009 |
Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Behavior Therapy; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Single-Blind Method; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2010 |
Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Topics: Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2009 |
Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2010 |
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Topics: Adult; Aged; Aged, 80 and over; Canada; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2010 |
Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.
Topics: Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence | 2010 |
Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.
Topics: Canada; Cost-Benefit Analysis; Female; Humans; Male; Mandelic Acids; Markov Chains; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2010 |
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Medical Records; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Placebos; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination; Young Adult | 2010 |
Prospective open label study of solifenacin for overactive bladder in children.
Topics: Child; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence | 2010 |
Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Taiwan; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2010 |
Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Canada; Dosage Forms; Double-Blind Method; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Young Adult | 2011 |
Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study.
Topics: Analysis of Variance; Female; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2011 |
Which single-item measures of overactive bladder symptom treatment correlate best with patient satisfaction?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Health Status; Humans; Male; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Patient Satisfaction; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2011 |
Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urodynamics | 2011 |
Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary.
Topics: Aged; Double-Blind Method; Female; Humans; Japan; Male; Medical Records; Middle Aged; Muscarinic Antagonists; Nocturia; Quinuclidines; Sleep; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2011 |
[Treatment with solifenacin reduces urinary urgency and improves quality of life. Results of the non-interventional CAP-study].
Topics: Adult; Aged; Cooperative Behavior; Female; Germany; Humans; Interdisciplinary Communication; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2011 |
Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Prostatism; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2011 |
Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
Topics: Adult; Female; Humans; Hydrocephalus, Normal Pressure; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Ventriculoperitoneal Shunt | 2012 |
The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
Topics: Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Placebos; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.
Topics: Aged; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2013 |
Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2013 |
Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Method; Female; Humans; Least-Squares Analysis; Male; Mandelic Acids; Memory; Muscarinic Antagonists; Quinuclidines; Risk Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urological Agents | 2013 |
Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study.
Topics: Benzofurans; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Pyrrolidines; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
Topics: Aged; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Muscarinic Antagonists; Population; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
Topics: Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Polyuria; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
Topics: Aged; Analgesics; Benzilates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Muscarinic Antagonists; Nortropanes; Prospective Studies; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2007 |
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; United States; Urinary Bladder, Overactive | 2006 |
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Visual Acuity; Xerostomia | 2007 |
Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Black or African American; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Topics: Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Safety; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urination | 2007 |
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Topics: Adult; Aged; Benzilates; Constipation; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Xerostomia | 2007 |
[A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2007 |
Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Attitude to Health; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
Topics: Activities of Daily Living; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Health Services; Humans; Male; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Patient Acceptance of Health Care; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
132 other study(ies) available for solifenacin succinate and Urinary Bladder, Overactive
| Article | Year |
|---|---|
Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Topics: Aged; Canada; Case-Control Studies; Dementia; Humans; Muscarinic Antagonists; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2022 |
Impact of Bladder Wall Thickness on the Outcomes of Antimuscarinic Treatment in Women with Overactive Bladder.
Topics: Female; Humans; Muscarinic Antagonists; Solifenacin Succinate; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2022 |
Patient Experience of Antimuscarinic Treatment for Overactive Bladder: A Qualitative Exploration of Online Forum Content.
Topics: Female; Humans; Male; Muscarinic Antagonists; Patient Outcome Assessment; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2022 |
Risk of delirium associated with antimuscarinics in older adults: A case-time-control study.
Topics: Aged; Aged, 80 and over; Cholinergic Antagonists; Delirium; Humans; Muscarinic Antagonists; Solifenacin Succinate; Urinary Bladder, Overactive | 2022 |
Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cholinergic Antagonists; Dementia; Humans; Muscarinic Antagonists; Solifenacin Succinate; Urinary Bladder, Overactive | 2022 |
Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database.
Topics: Aged; Aged, 80 and over; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Retention | 2022 |
Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice.
Topics: Acetanilides; Animals; Carbachol; Female; Mice; Muscarinic Antagonists; Solifenacin Succinate; Stress, Psychological; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2022 |
Urobiome changes differ based on OAB treatment in adult females.
Topics: Acetanilides; Adult; Drug Therapy, Combination; Female; Humans; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2023 |
Cold stress-induced bladder overactivity in type 2 diabetic mellitus rats is mitigated by the combination of a M
Topics: Adrenergic Agonists; Adrenergic beta-3 Receptor Agonists; Animals; Cold-Shock Response; Diabetes Mellitus, Type 2; Female; Muscarinic Antagonists; Quality of Life; Rats; Receptors, Adrenergic; Receptors, Muscarinic; RNA, Messenger; Solifenacin Succinate; Urinary Bladder; Urinary Bladder, Overactive | 2023 |
Patient Perception of Bladder Condition after Treatment with Solifenacin and Tolterodine in Overactive Bladder Patients.
Topics: Benzhydryl Compounds; Cresols; Cross-Sectional Studies; Humans; Nepal; Perception; Phenylpropanolamine; Solifenacin Succinate; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder; Urinary Bladder Diseases; Urinary Bladder, Overactive | 2023 |
[Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
Topics: Acetanilides; Humans; Muscarinic Antagonists; Prescriptions; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents | 2023 |
Fluorimetric study on a novel FDA-approved combination used for the treatment of overactive bladder syndrome in different matrices.
Topics: Drug Therapy, Combination; Fluorometry; Humans; Solifenacin Succinate; Time; Urinary Bladder, Overactive | 2024 |
Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways.
Topics: Acetanilides; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Duloxetine Hydrochloride; Female; Locomotion; Rats; Rats, Wistar; Signal Transduction; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Therapeutic effect of myofascial trigger point electroacupuncture technology on the treatment of overactive bladder syndrome in female.
Topics: Electroacupuncture; Female; Humans; Quality of Life; Solifenacin Succinate; Treatment Outcome; Trigger Points; Urinary Bladder, Overactive | 2020 |
[The Efficacy of Fesoterodine Switched from Solifenacin for Overactive Bladder Patients].
Topics: Benzhydryl Compounds; Humans; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Comparison of the effects of trospium and solifenacin on intraocular pressure and tear secretion in patients with overactive bladder.
Topics: Adult; Aged; Humans; Intraocular Pressure; Middle Aged; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
New Indication for Solifenacin.
Topics: Administration, Oral; Humans; Hydrogen-Ion Concentration; Solifenacin Succinate; Suspensions; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2020 |
Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study.
Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
[Sacral electrical neurostimulation in the refractory pediatric overactive bladder].
Topics: Child; Electric Stimulation Therapy; Humans; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2020 |
Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
Topics: Acetanilides; Adolescent; Age Factors; Child; Child, Preschool; Female; Humans; Male; Retrospective Studies; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
[A Case of Detrusor Hyperactivity with Impaired Contractility (DHIC) after Transverse Myelitis].
Topics: Adult; Humans; Male; Myelitis, Transverse; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urodynamics | 2021 |
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Catheterization; Cohort Studies; Female; Humans; Incidence; Male; Middle Aged; Muscarinic Antagonists; Prostatic Diseases; Randomized Controlled Trials as Topic; Residual Volume; Risk; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Retention; Urodynamics; Urological Agents | 2017 |
Editorial Comment.
Topics: Botulinum Toxins, Type A; Double-Blind Method; Humans; Solifenacin Succinate; Urinary Bladder, Overactive | 2017 |
Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Young Adult | 2017 |
Could Reduced Fluid Intake Cause the Placebo Effect Seen in Overactive Bladder Clinical Trials? Analysis of a Large Solifenacin Integrated Database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Drinking; Female; Humans; Male; Middle Aged; Placebo Effect; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents; Young Adult | 2017 |
Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Topics: Adolescent; Adult; Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Medication Adherence; Middle Aged; Obesity; Quality of Life; Sex Factors; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2017 |
Re: Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients with Benign Prostatic Hyperplasia.
Topics: Humans; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Urinary Bladder, Overactive | 2017 |
Overactive Bladder Symptom Scores responsiveness before and after anticholinergic treatment in women with overactive bladder: The pilot study.
Topics: Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Pilot Projects; Solifenacin Succinate; Urinary Bladder, Overactive; Urination | 2017 |
[Description of a clinical typology specific to men whose urinary symptoms require anticholinergic treatment].
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Follow-Up Studies; France; Humans; Male; Middle Aged; Patient Satisfaction; Patient Selection; Prospective Studies; Risk Factors; Solifenacin Succinate; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urological Agents | 2017 |
Editorial Comment.
Topics: Adolescent; Child; Humans; Solifenacin Succinate; Urinary Bladder, Overactive | 2017 |
Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Humans; Longitudinal Studies; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Patient Reported Outcome Measures; Patient Satisfaction; Quality of Life; Solifenacin Succinate; Sweden; Urinary Bladder, Overactive; Urological Agents | 2017 |
American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA).
Topics: Acetanilides; Administration, Intranasal; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials, Phase III as Topic; Deamino Arginine Vasopressin; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Hydrogels; Mitomycin; Multicenter Studies as Topic; Nocturia; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; United States; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urology | 2017 |
Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
Topics: Aged; Case-Control Studies; Cognition; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Mental Status and Dementia Tests; Middle Aged; Prostatic Hyperplasia; Quality of Life; Solifenacin Succinate; Sulfonamides; Tamsulosin; Urinary Bladder, Overactive; Urological Agents | 2018 |
Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?
Topics: Acetanilides; Cholinergic Antagonists; Drug Therapy, Combination; Follow-Up Studies; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2017 |
Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Antidiuretic Agents; Deamino Arginine Vasopressin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscarinic Antagonists; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2017 |
Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
Topics: Acetanilides; Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Retrospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2018 |
Evaluating the effect of three newly approved overactive bladder syndrome treating agents on parotid and submandibular salivary glands: Modulation of CXCL10 expression.
Topics: Animals; Benzilates; Benzofurans; Chemokine CXCL10; Immunohistochemistry; Male; Nortropanes; Parotid Gland; Polymerase Chain Reaction; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reference Standards; Salivation; Solifenacin Succinate; Staining and Labeling; Submandibular Gland; Urinary Bladder, Overactive | 2018 |
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications.
Topics: Acetanilides; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Databases as Topic; Drug Industry; Drug Prescriptions; Humans; Indoles; Medicare Part D; Practice Patterns, Physicians'; Solifenacin Succinate; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents; Urology | 2018 |
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Prospective Studies; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2019 |
Combination Therapy for Overactive Bladder: Who Approves?
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2018 |
Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eu
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2019 |
Comparison of Oral Sodium Bicarbonate and Solifenacin Treatment in Female Overactive Bladder Patients With Acidic Urine pH.
Topics: Aged; Biomarkers; Female; Humans; Hydrogen-Ion Concentration; Middle Aged; Muscarinic Antagonists; Prospective Studies; Random Allocation; Sodium Bicarbonate; Solifenacin Succinate; Urinary Bladder, Overactive | 2020 |
Re: Efficacy and Safety of Combinations of Mirabegron and Solifenacin Compared with Monotherapy and Placebo in Patients with Overactive Bladder (SYNERGY Study).
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2018 |
Topics: Adolescent; Child; Humans; Solifenacin Succinate; Urinary Bladder, Overactive | 2018 |
Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2019 |
Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe.
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Europe; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Solifenacin Succinate; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
Overactive bladder - pharmacological treatment.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Antidepressive Agents; Benzilates; Benzofurans; Brazil; Clinical Decision-Making; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Pyrrolidines; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
RE: Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2019 |
A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzofurans; Denmark; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Norway; Practice Patterns, Physicians'; Prospective Studies; Pyrrolidines; Registries; Solifenacin Succinate; Sweden; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
Reply from authors re: Jean-Nicolas Cornu. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg. Eur Urol 2013;64:82-3.
Topics: Aging; Cognition; Cognitive Dysfunction; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urological Agents | 2013 |
Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
Topics: Aged; Area Under Curve; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Product Surveillance, Postmarketing; Prospective Studies; Quinuclidines; ROC Curve; Sex Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics; Urological Agents | 2014 |
Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cresols; Databases, Pharmaceutical; Drug Substitution; Female; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Norway; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2013 |
Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Cresols; Humans; Incontinence Pads; Mandelic Acids; Markov Chains; Medication Adherence; Models, Economic; Muscarinic Antagonists; Patient Dropouts; Phenylpropanolamine; Quality-Adjusted Life Years; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urinary Incontinence | 2013 |
Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder.
Topics: Aged; Female; Humans; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Risk Factors; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Time Factors; Treatment Failure; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2013 |
Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Benzilates; Cresols; Cross-Sectional Studies; Female; Humans; Imidazoles; Japan; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Topics: Activities of Daily Living; Adult; Aged; Benzhydryl Compounds; Comorbidity; Cresols; Cross-Sectional Studies; Drug Substitution; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Observational Studies as Topic; Patient Preference; Patient Satisfaction; Personal Satisfaction; Phenylpropanolamine; Physicians; Propensity Score; Quinuclidines; Retrospective Studies; Sample Size; Solifenacin Succinate; Tetrahydroisoquinolines; Therapeutic Equivalency; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2014 |
Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study.
Topics: Adult; Aged; Aged, 80 and over; Cognition; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2014 |
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.
Topics: Aged; Benzhydryl Compounds; Cholinergic Agents; Cost-Benefit Analysis; Cresols; Female; Health Care Costs; Humans; Male; Phenylpropanolamine; Prevalence; Primary Health Care; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Spain; Syndrome; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2013 |
Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective?
Topics: Aged; Aged, 80 and over; Female; Humans; Middle Aged; Muscarinic Antagonists; Postoperative Complications; Prospective Studies; Quinuclidines; Solifenacin Succinate; Suburethral Slings; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).
Topics: Aged; Aged, 80 and over; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Symptom Assessment; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Managing overactive bladder symptoms in a palliative care setting.
Topics: Aged, 80 and over; Butylscopolammonium Bromide; Cholinergic Antagonists; Humans; Incontinence Pads; Male; Muscarinic Antagonists; Palliative Care; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urinary Tract Infections | 2014 |
Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Female; Health Care Costs; Health Resources; Humans; Male; Muscarinic Antagonists; Retrospective Studies; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Vulnerable Populations | 2014 |
The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service.
Topics: Benzilates; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Germany; Health Services; Humans; Medication Adherence; Models, Economic; National Health Programs; Nortropanes; Quality-Adjusted Life Years; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; United Kingdom; Urinary Bladder, Overactive; Urological Agents | 2014 |
The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment.
Topics: Adult; Aged; Aged, 80 and over; Female; Glaucoma; Humans; Intraocular Pressure; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects.
Topics: Adult; Ankle Brachial Index; Blood Pressure; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Middle Aged; Muscarinic Antagonists; Nocturia; Pressure; Solifenacin Succinate; Tolterodine Tartrate; Urethra; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urodynamics; Vascular Stiffness | 2014 |
The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Topics: Adult; Aged; China; Female; Humans; Language; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Reproducibility of Results; Solifenacin Succinate; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2014 |
Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Benzilates; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Nortropanes; Prostatic Hyperplasia; Solifenacin Succinate; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2015 |
Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
Topics: Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
The evolving picture of lower urinary tract symptom management.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Solifenacin Succinate; Sulfonamides; Urinary Bladder; Urinary Bladder, Overactive; Urinary Retention; Urological Agents | 2015 |
A prospective, observational study to assess the association between dry mouth and solifenacin treatment in patients with overactive bladder syndrome.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia; Young Adult | 2015 |
Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive | 2015 |
Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents | 2015 |
Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.
Topics: Adult; Biomarkers; Case-Control Studies; Creatinine; Humans; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Prospective Studies; Solifenacin Succinate; Symptom Assessment; Urinary Bladder, Overactive | 2016 |
Combination of solifenacin and mirabegron for overactive bladder management.
Topics: Acetanilides; Female; Humans; Male; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2015 |
[ASSESSMENT OF EFFICIENCY OF TREATMENT OF OVERACTIVE BLADDER IN ELDERLY PATIENTS].
Topics: Adrenergic alpha-1 Receptor Antagonists; Age Factors; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Prazosin; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2015 |
Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.
Topics: Adult; Benzhydryl Compounds; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Primary Health Care; Retrospective Studies; Sick Leave; Solifenacin Succinate; Spain; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Work Performance | 2015 |
Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.
Topics: Benzhydryl Compounds; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Primary Health Care; Retrospective Studies; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2016 |
The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?
Topics: Adult; Aged; Biomarkers; Brain-Derived Neurotrophic Factor; Chemokine CCL2; Female; Humans; Male; Middle Aged; Nerve Growth Factor; Solifenacin Succinate; Treatment Failure; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2017 |
Ovariectomy May Induce Detrusor Overactivity in Rats: The Therapeutic Role of Rho Kinase Inhibition.
Topics: Animals; Female; Muscarinic Antagonists; Ovariectomy; Postoperative Complications; Rats; Rats, Wistar; rho-Associated Kinases; Solifenacin Succinate; Urinary Bladder, Overactive | 2016 |
Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study.
Topics: Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2016 |
Do Effects on Bowel Patterns Imposed by Solifenacin Always Have Negative Impacts on Treating Patients with Overactive Bladder (OAB)?
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Irritable Bowel Syndrome; Middle Aged; Muscarinic Antagonists; Pilot Projects; Prospective Studies; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Young Adult | 2016 |
Incontinence: Adding mirabegron to solifenacin improves patient outcomes.
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2016 |
Re: A Randomized, Controlled Trial of Effectiveness and Safety of Management of OAB Symptoms in Elderly Men and Women with Standard-Dosed Combination of Solifenacin and Mirabegron.
Topics: Acetanilides; Aged; Female; Humans; Male; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Is overactive bladder a nervous or bladder disorder? Autonomic imaging in patients with overactive bladder via dynamic pupillometry.
Topics: Adult; Autonomic Nervous System Diseases; Case-Control Studies; Female; Humans; Middle Aged; Muscarinic Antagonists; Parasympathetic Nervous System; Pupil; Pupil Disorders; Solifenacin Succinate; Time Factors; Urinary Bladder; Urinary Bladder, Overactive; Young Adult | 2017 |
Combined treatment with a β
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cold Temperature; Disease Models, Animal; Drug Therapy, Combination; Female; Muscarinic Antagonists; Rats; Rats, Inbred SHR; Solifenacin Succinate; Stress, Physiological; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents | 2017 |
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Severity of Illness Index; Solifenacin Succinate; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Vision Disorders; Xerostomia; Young Adult | 2018 |
Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder.
Topics: Female; Humans; Medication Adherence; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Topics: Acetanilides; Double-Blind Method; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder.
Topics: Adult; Aged; Biomarkers; Creatinine; Female; Humans; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Nocturia; Proportional Hazards Models; Prospective Studies; Recurrence; ROC Curve; Solifenacin Succinate; Urinary Bladder; Urinary Bladder, Overactive | 2017 |
Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder.
Topics: Administration, Oral; Adult; Aged; Dry Eye Syndromes; Female; Humans; Intraocular Pressure; Middle Aged; Muscarinic Antagonists; Nasolacrimal Duct; Prospective Studies; Solifenacin Succinate; Tears; Urinary Bladder, Overactive | 2017 |
Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2017 |
Profile of oab patient on treatment with flexible-dose antimuscarinic drugs in daily clinical practice.
Topics: Benzhydryl Compounds; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Solifenacin Succinate; Urinary Bladder, Overactive | 2016 |
Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects.
Topics: Aged; Aged, 80 and over; Cognition; Cognition Disorders; Female; Germany; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive | 2017 |
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-Blind Multicentre Phase 3B Study (BESIDE).
Topics: Acetanilides; Double-Blind Method; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2017 |
Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.
Topics: Acetanilides; Cholinergic Antagonists; Humans; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents | 2017 |
[Using autonomous electrostimulation device Erektron in treating female overactive bladder].
Topics: Adult; Aged; Cholinergic Antagonists; Combined Modality Therapy; Electric Stimulation Therapy; Female; Humans; Middle Aged; Solifenacin Succinate; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urinary Incontinence, Urge; Young Adult | 2016 |
[Overactive bladder. When it's pressing, immediate help is indicated].
Topics: Clinical Trials as Topic; Female; Humans; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2008 |
The cost utility of solifenacin in the treatment of overactive bladder.
Topics: Adult; Cost-Benefit Analysis; Diapers, Adult; Drug Costs; Female; Humans; Male; Markov Chains; Muscarinic Antagonists; Patient Compliance; Quality-Adjusted Life Years; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman.
Topics: Aged, 80 and over; Electrocardiography; Female; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Syncope; Tetrahydroisoquinolines; Torsades de Pointes; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
[Urinary urgency].
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Muscarinic Antagonists; Nocturia; Quinuclidines; Sleep Deprivation; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2008 |
Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
Topics: Aged; Benzhydryl Compounds; Benzofurans; Cresols; Cystectomy; Female; Humans; Male; Middle Aged; Mucous Membrane; Muscarinic Antagonists; Phenylpropanolamine; Prostatectomy; Pyrrolidines; Quinuclidines; Quinuclidinyl Benzilate; Radioligand Assay; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive | 2009 |
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Muscarinic Antagonists; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Terminology as Topic; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Decision Support Techniques; Female; Finland; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.
Topics: Benzhydryl Compounds; Computer Simulation; Cost-Benefit Analysis; Cresols; Humans; Italy; Markov Chains; Muscarinic Antagonists; Pharmacogenetics; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2009 |
Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study.
Topics: Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cresols; Female; Health Care Costs; Humans; Muscarinic Antagonists; Pharmacoepidemiology; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Registries; Retrospective Studies; Solifenacin Succinate; Sweden; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Solifenacin for therapy resistant overactive bladder.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Male; Muscarinic Antagonists; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis.
Topics: Aged; Efficiency; Female; Health Resources; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Topics: Benzhydryl Compounds; Benzilates; Cost-Benefit Analysis; Cresols; Decision Trees; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2010 |
Pediatrics: combining antimuscarinics shows promise for overactive bladder.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Pediatrics; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urodynamics | 2010 |
[Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results].
Topics: Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence | 2010 |
Overactive bladder syndrome: what is the role of evidence of detrusor overactivity in the cystometric study?
Topics: Adult; Aged; Aged, 80 and over; Cystostomy; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urodynamics | 2010 |
Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2011 |
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Benzhydryl Compounds; Benzofurans; Blood-Brain Barrier; Brain; Cell Line; Chromatography, High Pressure Liquid; Cresols; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Solifenacin Succinate; Tandem Mass Spectrometry; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2011 |
Solifenacin may improve sleep quality in patients with overactive bladder and sleep disturbance.
Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Quinuclidines; Sleep Wake Disorders; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2011 |
[Treatment for overactive bladder].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cooperative Behavior; Cross-Sectional Studies; General Practice; Humans; Interdisciplinary Communication; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Quinuclidines; Sex Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urodynamics; Young Adult | 2011 |
Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Creatinine; Drug Resistance; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Quinuclidines; Solifenacin Succinate; Syndrome; Taiwan; Tetrahydroisoquinolines; Time Factors; Treatment Failure; Up-Regulation; Urinary Bladder; Urinary Bladder, Overactive; Young Adult | 2011 |
Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome.
Topics: Aged; Diagnostic Techniques, Urological; Equipment Design; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Antagonists; Predictive Value of Tests; Quinuclidines; Reproducibility of Results; Sensation; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2012 |
Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Analysis of Variance; Animals; Disease Models, Animal; Diterpenes; Drug Therapy, Combination; Female; Infarction, Middle Cerebral Artery; Muscarinic Antagonists; Muscle Contraction; Organ Size; Quinuclidines; Rats; Rats, Sprague-Dawley; Solifenacin Succinate; Statistics, Nonparametric; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder; Urinary Bladder, Overactive | 2011 |
Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects.
Topics: Clinical Trials as Topic; Forecasting; Humans; Logistic Models; Models, Biological; Muscarinic Antagonists; Placebo Effect; Placebos; Quinuclidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sample Size; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2013 |
Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion.
Topics: Chi-Square Distribution; Compliance; Female; Humans; Longitudinal Studies; Male; Muscarinic Antagonists; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Spinal Cord Injuries; Switzerland; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2013 |
Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg.
Topics: Aging; Cognition; Cognitive Dysfunction; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urological Agents | 2013 |
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Topics: Analysis of Variance; Benzhydryl Compounds; Controlled Clinical Trials as Topic; Cresols; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
Topics: Aged; Gastroesophageal Reflux; Humans; Meta-Analysis as Topic; Muscarinic Antagonists; Quinuclidines; Respiratory Aspiration; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2006 |
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzilates; Benzofurans; Binding, Competitive; Carbachol; CHO Cells; Cholinergic Agonists; Cresols; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Mandelic Acids; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; N-Methylscopolamine; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Transfection; Urinary Bladder; Urinary Bladder, Overactive; Urination | 2007 |
Solifenacin succinate (VESIcare): overactive bladder therapy.
Topics: Contraindications; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2006 |
An unusual cause of postoperative detrusor overactivity.
Topics: Adult; Fallopian Tube Diseases; Female; Humans; Hysterectomy; Muscarinic Antagonists; Prolapse; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urodynamics | 2007 |
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Topics: Analysis of Variance; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Photodistributed lichenoid drug eruption secondary to solifenacin.
Topics: Anti-Ulcer Agents; Anticholesteremic Agents; Drug Eruptions; Drug Interactions; Humans; Lichenoid Eruptions; Male; Middle Aged; Muscarinic Antagonists; Myocardial Ischemia; Quinine; Quinuclidines; Solifenacin Succinate; Sunscreening Agents; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
Solifenacin-induced small bowel pseudo-obstruction.
Topics: Aged, 80 and over; Female; Humans; Intestinal Pseudo-Obstruction; Intestine, Small; Muscarinic Antagonists; Positron-Emission Tomography; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tomography, X-Ray; Urinary Bladder, Overactive | 2008 |